US equities |
NVDA $239.94 ▲+2.56% SPCX $169.39 ▲+6.56% MU $1,063.20 ▼-1.09% TSLA $379.84 ▲+2.50% SNDK $1,704.54 ▼-0.90% MSFT $528.55 ▲+2.13% INTC $116.07 ▼-2.73% META $742.89 ▲+2.03%
FinancialContent

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

56.63 -0.53 (-0.93%)
Delayed Quote Updated: 3:39 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Looking Into Royalty Pharma's Recent Short Interest ↗
 
Via Benzinga
News headline image
NASDAQ:RPRX is an undervalued gem with solid fundamentals. ↗
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX), an undervalued stock with good fundamentals. 
Via Chartmill
News headline image
The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio ↗
With a possible rotation away from the technology space, these are the undervalued healthcare stocks to consider. 
Via InvestorPlace
News headline image
For those who appreciate value investing, NASDAQ:RPRX is a compelling option with its solid fundamentals. ↗
When you look at ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
News headline image
Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Earnings Scheduled For February 15, 2024 ↗
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
News headline image
Royalty Pharma's Earnings: A Preview ↗
 
Via Benzinga
News headline image
NASDAQ:RPRX is an undervalued gem with solid fundamentals. ↗
Despite its impressive fundamentals, ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) remains undervalued. 
Via Chartmill
News headline image
NASDAQ:RPRX: good value for what you're paying. ↗
Despite its impressive fundamentals, ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) remains undervalued. 
Via Chartmill
News headline image
Wall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 Months ↗
Analysts are quite bullish about these beaten-down stocks. 
Via The Motley Fool
News headline image
Royalty Pharma Reports Q4 and Full Year 2023 Results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
3 Biotech Stocks to Buy for the Next Bull Run: February 2024 ↗
These are the biotech stocks to buy that you must have on your watchlist for the coming bull run. It could get started as soon as this month. 
Via InvestorPlace
News headline image
NASDAQ:RPRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) is an undervalued gem with solid fundamentals. 
Via Chartmill
News headline image
Royalty Pharma's Earnings Outlook ↗
 
Via Benzinga
News headline image
How Risky Is Royalty Pharma’s Dividend? ↗
Royalty Pharma just announced a 5% dividend increase, its fourth raise in a row. It has boosted the dividend every year since it began paying one in 2020. The new $0.21 per share quarterly dividend... 
Via Talk Markets
News headline image
Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Top Stocks That Just Increased Their Dividends ↗
There are several reasons why investors tend to favor stocks that have had a dividend increase. 
Via Talk Markets
News headline image
Royalty Pharma Announces Dividend Increase
From Royalty Pharma plc
Via GlobeNewswire
News headline image
NASDAQ:RPRX appears to be flying under the radar despite its strong fundamentals. ↗
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) is an undervalued gem with solid fundamentals. 
Via Chartmill
News headline image
Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
NASDAQ:RPRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
News headline image
Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Royalty Pharma Reports Third Quarter 2023 Results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Why PTC Therapeutics Soared 15% Higher Today ↗
The company scored a $1 billion upfront payment for expanding a commercial partnership. 
Via The Motley Fool
News headline image
Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Declares Fourth Quarter 2023 Dividend
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Appoints Eric Schneider as Chief Technology Officer
From Royalty Pharma plc
Via GlobeNewswire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >